Xeris Biopharma Holdings Inc (XERS)

$2.61

+0.05

(+2.15%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.54
    $2.64
    $2.61
    downward going graph

    2.68%

    Downside

    Day's Volatility :3.64%

    Upside

    0.99%

    downward going graph
  • $1.46
    $3.26
    $2.61
    downward going graph

    44.06%

    Downside

    52 Weeks Volatility :55.21%

    Upside

    19.94%

    downward going graph

Returns

PeriodXeris Biopharma Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
46.0%
6.5%
0.0%
6 Months
2.61%
7.1%
0.0%
1 Year
4.71%
9.8%
0.0%
3 Years
40.38%
14.2%
-20.2%

Highlights

Market Capitalization
376.6M
Book Value
- $0.06
Earnings Per Share (EPS)
-0.47
Wall Street Target Price
4.58
Profit Margin
-37.58%
Operating Margin TTM
-35.05%
Return On Assets TTM
-8.55%
Return On Equity TTM
-617.16%
Revenue TTM
171.4M
Revenue Per Share TTM
1.24
Quarterly Revenue Growth YOY
22.400000000000002%
Gross Profit TTM
87.6M
EBITDA
-32.7M
Diluted Eps TTM
-0.47
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.4
EPS Estimate Next Year
-0.2
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Xeris Biopharma Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 75.48%

Current $2.61
Target $4.58

Company Financials

FY18Y/Y Change
Revenue
2.5M
↑ 58.42%
Net Income
-60.1M
↑ 126.26%
Net Profit Margin
-2.4K%
↓ 730.76%
FY19Y/Y Change
Revenue
2.7M
↑ 10.43%
Net Income
-125.6M
↑ 109.02%
Net Profit Margin
-4.6K%
↓ 2176.2%
FY20Y/Y Change
Revenue
20.2M
↑ 640.45%
Net Income
-91.1M
↓ 27.42%
Net Profit Margin
-452.2%
↑ 4161.32%
FY21Y/Y Change
Revenue
49.6M
↑ 146.04%
Net Income
-122.7M
↑ 34.66%
Net Profit Margin
-247.48%
↑ 204.72%
FY22Y/Y Change
Revenue
110.2M
↑ 122.32%
Net Income
-94.7M
↓ 22.87%
Net Profit Margin
-85.86%
↑ 161.62%
FY23Y/Y Change
Revenue
163.9M
↑ 48.68%
Net Income
-62.3M
↓ 34.23%
Net Profit Margin
-37.98%
↑ 47.88%
Q4 FY22Q/Q Change
Revenue
38.0M
↑ 14.5%
Net Income
-19.8M
↓ 25.43%
Net Profit Margin
-52.2%
↑ 27.95%
Q1 FY23Q/Q Change
Revenue
33.2M
↓ 12.66%
Net Income
-16.8M
↓ 15.16%
Net Profit Margin
-50.71%
↑ 1.49%
Q2 FY23Q/Q Change
Revenue
38.0M
↑ 14.5%
Net Income
-19.8M
↑ 17.87%
Net Profit Margin
-52.2%
↓ 1.49%
Q3 FY23Q/Q Change
Revenue
48.3M
↑ 27.13%
Net Income
-12.2M
↓ 38.57%
Net Profit Margin
-25.23%
↑ 26.97%
Q4 FY23Q/Q Change
Revenue
44.4M
↓ 8.13%
Net Income
-13.4M
↑ 9.85%
Net Profit Margin
-30.16%
↓ 4.93%
Q1 FY24Q/Q Change
Revenue
40.6M
↓ 8.45%
Net Income
-19.0M
↑ 41.75%
Net Profit Margin
-46.71%
↓ 16.55%
FY18Y/Y Change
Total Assets
120.0M
↑ 166.74%
Total Liabilities
44.6M
↓ 56.61%
FY19Y/Y Change
Total Assets
109.0M
↓ 9.2%
Total Liabilities
94.6M
↑ 111.89%
FY20Y/Y Change
Total Assets
159.2M
↑ 46.03%
Total Liabilities
125.4M
↑ 32.62%
FY21Y/Y Change
Total Assets
304.4M
↑ 91.24%
Total Liabilities
209.1M
↑ 66.78%
FY22Y/Y Change
Total Assets
344.5M
↑ 13.2%
Total Liabilities
299.3M
↑ 43.13%
FY23Y/Y Change
Total Assets
322.6M
↓ 6.36%
Total Liabilities
329.4M
↑ 10.04%
Q4 FY22Q/Q Change
Total Assets
328.8M
↑ 2.31%
Total Liabilities
315.1M
↑ 8.18%
Q1 FY23Q/Q Change
Total Assets
321.4M
↓ 2.26%
Total Liabilities
291.3M
↓ 7.56%
Q2 FY23Q/Q Change
Total Assets
328.8M
↑ 2.31%
Total Liabilities
315.1M
↑ 8.18%
Q3 FY23Q/Q Change
Total Assets
327.8M
↓ 0.3%
Total Liabilities
323.9M
↑ 2.79%
Q4 FY23Q/Q Change
Total Assets
340.8M
↑ 3.97%
Total Liabilities
347.6M
↑ 7.3%
Q1 FY24Q/Q Change
Total Assets
336.6M
↓ 1.23%
Total Liabilities
345.8M
↓ 0.51%
FY18Y/Y Change
Operating Cash Flow
-56.3M
↑ 128.19%
Investing Cash Flow
-68.3M
↑ 9651.57%
Financing Cash Flow
128.2M
↑ 264.87%
FY19Y/Y Change
Operating Cash Flow
-104.3M
↑ 85.41%
Investing Cash Flow
-2.4M
↓ 96.51%
Financing Cash Flow
80.5M
↓ 37.19%
FY20Y/Y Change
Operating Cash Flow
-80.6M
↓ 22.8%
Investing Cash Flow
-27.4M
↑ 1050.02%
Financing Cash Flow
126.1M
↑ 56.54%
FY21Y/Y Change
Operating Cash Flow
-95.5M
↑ 18.59%
Investing Cash Flow
98.0M
↓ 457.47%
Financing Cash Flow
27.2M
↓ 78.39%
FY22Y/Y Change
Operating Cash Flow
-102.9M
↑ 7.7%
Investing Cash Flow
34.5M
↓ 64.82%
Financing Cash Flow
127.5M
↑ 367.84%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.7M
↓ 47.42%
Investing Cash Flow
9.2M
↑ 36.65%
Financing Cash Flow
556.0K
↓ 164.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-26.1M
↑ 90.19%
Investing Cash Flow
8.5M
↓ 7.81%
Financing Cash Flow
-863.0K
↓ 255.22%
Q2 FY23Q/Q Change
Operating Cash Flow
-13.7M
↓ 47.42%
Investing Cash Flow
8.5M
↑ 0.0%
Financing Cash Flow
556.0K
↓ 164.43%
Q3 FY23Q/Q Change
Operating Cash Flow
-14.6M
↑ 6.3%
Investing Cash Flow
14.7M
↑ 73.39%
Financing Cash Flow
-72.0K
↓ 112.95%

Technicals Summary

Sell

Neutral

Buy

Xeris Biopharma Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc
16.14%
2.61%
4.71%
40.38%
40.38%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc
NA
NA
NA
-0.4
-6.17
-0.09
NA
-0.06
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc
Buy
$376.6M
40.38%
NA
-37.58%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Xeris Biopharma Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 48.32M → 40.63M (in $), with an average decrease of 8.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -12.18M → -18.98M (in $), with an average decrease of 25.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 56.9%

Institutional Holdings

  • BlackRock Inc

    6.72%

  • Vanguard Group Inc

    5.13%

  • Caxton Corp

    3.45%

  • MPM Oncology Impact Management LP

    2.81%

  • State Street Corporation

    2.17%

  • Geode Capital Management, LLC

    2.05%

Company Information

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Organization
Xeris Biopharma Holdings Inc
Employees
377
CEO
Mr. Paul R. Edick
Industry
Health Technology

Discover More

FAQs